Symbols / CMMB $1.69 +1.87% Chemomab Therapeutics Ltd.
CMMB Chart
About
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.
Fundamentals
Scroll to Statements| Market Cap | 12.17M | Enterprise Value | 962.03M | Income | -8.99M | Sales | — | Book/sh | 1.72 | Cash/sh | 0.02 |
| Dividend Yield | — | Payout | 0.00% | Employees | — | IPO | — | P/E | — | Forward P/E | -56.33 |
| PEG | — | P/S | — | P/B | 0.99 | P/C | — | EV/EBITDA | -101.30 | EV/Sales | — |
| Quick Ratio | 7.14 | Current Ratio | 9.08 | Debt/Eq | — | LT Debt/Eq | — | EPS (ttm) | -1.44 | EPS next Y | -0.03 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2026-03-19 | ROA | -38.86% | ROE | -69.54% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 7.20M | Shs Float | 507.24M | Short Float | 0.68% |
| Short Ratio | 0.93 | Short Interest | — | 52W High | 5.88 | 52W Low | 1.35 | Beta | 0.58 | Avg Volume | 70.00K |
| Volume | 10.42K | Target Price | $15.00 | Recom | None | Prev Close | $1.66 | Price | $1.69 | Change | 1.87% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$15.00
Mean price target
2. Current target
$1.69
Latest analyst target
3. DCF / Fair value
$-20.50
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.69
Low
$5.00
High
$25.00
Mean
$15.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-08-27 | main | Oppenheimer | Outperform → Outperform | $25 |
| 2025-05-16 | main | Oppenheimer | Outperform → Outperform | $10 |
| 2025-02-20 | main | Maxim Group | Buy → Buy | $7 |
| 2024-11-15 | reit | Oppenheimer | Outperform → Outperform | $11 |
| 2024-05-13 | init | Maxim Group | — → Buy | $4 |
| 2024-05-06 | up | Oppenheimer | Perform → Outperform | $6 |
| 2024-03-08 | main | Oppenheimer | Perform → Perform | — |
| 2023-10-06 | init | Roth MKM | — → Buy | $7 |
| 2023-06-07 | down | Oppenheimer | Outperform → Perform | — |
| 2023-04-18 | main | Oppenheimer | — → Outperform | $7 |
| 2022-03-10 | main | Oppenheimer | — → Outperform | $20 |
| 2021-12-07 | init | Aegis Capital | — → Buy | $30 |
| 2021-05-26 | init | Cantor Fitzgerald | — → Overweight | $45 |
| 2021-05-07 | init | Oppenheimer | — → Outperform | $42 |
- CMMB (Chemomab Therapeutics Ltd. American Depositary Share) posts narrower Q4 2025 loss than estimates, while shares dip modestly. - Community Trade Ideas - Xã Thanh Hà Wed, 22 Apr 2026 21
- Chemomab Therapeutics (CMMB) director discloses ADS holdings and vested options - Stock Titan Fri, 10 Apr 2026 20
- Chemomab Therapeutics - Depositary Receipt (CMMB) price target decreased by 14.29% to 15.30 - MSN Sun, 19 Apr 2026 16
- CMMB Chemomab reports narrower than expected Q4 2025 loss as shares stay flat on zero quarterly revenue. - Trading Community - Xã Châu Thành Wed, 22 Apr 2026 20
- CMMB | Chemomab Therapeutics Ltd. American Institutional Ownership - Quiver Quantitative Wed, 27 Aug 2025 19
- Oppenheimer raises Chemomab stock price target to $25 on M&A potential - Investing.com Wed, 27 Aug 2025 07
- Chemomab Therapeutics Sets April 28, 2026 Shareholder Meeting to Vote on Capital Increase and Governance Matters - The Globe and Mail Sat, 21 Mar 2026 07
- Chemomab Therapeutics (CMMB) director lists vested stock option grants - Stock Titan ue, 31 Mar 2026 07
- What is market pressure on Chemomab (CMMB) Stock | Price at $1.69, Up 1.20% - Real Trader Insights - Cổng thông tin điện tử tỉnh Lào Cai Mon, 13 Apr 2026 07
- Chemomab (CMMB) director reports fully vested ADS stock options - Stock Titan Fri, 10 Apr 2026 07
- Chemomab (CMMB) Stock Throwback Trade (Near Lows) 2026-04-15 - Volatility Breakout - Xã Vĩnh Công hu, 16 Apr 2026 04
- Chemomab (CMMB) director discloses option-heavy initial share ownership - Stock Titan Fri, 10 Apr 2026 07
- Chemomab (CMMB) CFO details ADS, option and RSU holdings in Form 3 - Stock Titan Fri, 10 Apr 2026 07
- Chemomab (CMMB) CDO John Lawler details option and RSU holdings - Stock Titan Fri, 10 Apr 2026 07
- Chemomab (CMMB) CEO discloses ADS, RSU and stock option stakes - Stock Titan Fri, 10 Apr 2026 07
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
9.57
-35.09%
|
14.74
-42.11%
|
25.46
-10.77%
|
28.53
|
| Research And Development |
|
5.83
-48.50%
|
11.33
-38.38%
|
18.38
+8.27%
|
16.98
|
| Selling General And Administration |
|
3.73
+9.44%
|
3.41
-51.79%
|
7.08
-38.75%
|
11.56
|
| General And Administrative Expense |
|
3.73
+9.44%
|
3.41
-51.79%
|
7.08
-38.75%
|
11.56
|
| Salaries And Wages |
|
1.79
+13.19%
|
1.58
-59.22%
|
3.89
-39.54%
|
6.43
|
| Other Gand A |
|
1.38
+11.46%
|
1.24
-49.68%
|
2.46
-38.74%
|
4.02
|
| Total Expenses |
|
9.57
-35.09%
|
14.74
-42.11%
|
25.46
-10.77%
|
28.53
|
| Operating Income |
|
-9.57
+35.09%
|
-14.74
+42.11%
|
-25.46
+10.77%
|
-28.53
|
| EBITDA |
|
-9.50
+35.33%
|
-14.69
+42.16%
|
-25.39
+10.83%
|
-28.48
|
| Normalized EBITDA |
|
-9.50
+35.33%
|
-14.69
+42.16%
|
-25.39
+10.83%
|
-28.48
|
| Reconciled Depreciation |
|
0.07
+32.08%
|
0.05
-20.90%
|
0.07
+15.52%
|
0.06
|
| EBIT |
|
-9.57
+35.09%
|
-14.74
+42.11%
|
-25.46
+10.77%
|
-28.53
|
| Net Income |
|
-8.99
+35.50%
|
-13.95
+42.43%
|
-24.22
+12.39%
|
-27.65
|
| Pretax Income |
|
-8.99
+35.50%
|
-13.95
+42.43%
|
-24.22
+14.05%
|
-28.18
|
| Net Non Operating Interest Income Expense |
|
0.57
-27.96%
|
0.79
-35.86%
|
1.24
+250.71%
|
0.35
|
| Net Interest Income |
|
0.57
-27.96%
|
0.79
-35.86%
|
1.24
+250.71%
|
0.35
|
| Interest Income Non Operating |
|
0.57
-27.96%
|
0.79
-35.86%
|
1.24
|
—
|
| Interest Income |
|
0.57
-27.96%
|
0.79
-35.86%
|
1.24
|
—
|
| Tax Provision |
|
0.00
|
0.00
|
0.00
+100.00%
|
-0.53
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
-100.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-8.99
+35.50%
|
-13.95
+42.43%
|
-24.22
+12.39%
|
-27.65
|
| Net Income From Continuing Operation Net Minority Interest |
|
-8.99
+35.50%
|
-13.95
+42.43%
|
-24.22
+12.39%
|
-27.65
|
| Net Income From Continuing And Discontinued Operation |
|
-8.99
+35.50%
|
-13.95
+42.43%
|
-24.22
+12.39%
|
-27.65
|
| Net Income Continuous Operations |
|
-8.99
+35.50%
|
-13.95
+42.43%
|
-24.22
+12.39%
|
-27.65
|
| Normalized Income |
|
-8.99
+35.50%
|
-13.95
+42.43%
|
-24.22
+12.39%
|
-27.65
|
| Net Income Common Stockholders |
|
-8.99
+35.50%
|
-13.95
+42.43%
|
-24.22
+12.39%
|
-27.65
|
| Diluted EPS |
|
-1.44
+58.14%
|
-3.44
+58.25%
|
-8.24
+14.88%
|
-9.68
|
| Basic EPS |
|
-1.44
+58.14%
|
-3.44
+58.25%
|
-8.24
+14.88%
|
-9.68
|
| Basic Average Shares |
|
6.38
+57.16%
|
4.06
+38.15%
|
2.94
+3.26%
|
2.84
|
| Diluted Average Shares |
|
6.38
+57.16%
|
4.06
+38.15%
|
2.94
+3.26%
|
2.84
|
| Diluted NI Availto Com Stockholders |
|
-8.99
+35.50%
|
-13.95
+42.43%
|
-24.22
+12.39%
|
-27.65
|
| Insurance And Claims |
|
0.50
-7.25%
|
0.54
-16.98%
|
0.65
-40.22%
|
1.08
|
| Rent And Landing Fees |
|
0.06
+20.00%
|
0.05
-38.27%
|
0.08
+237.50%
|
0.02
|
| Rent Expense Supplemental |
|
0.06
+20.00%
|
0.05
-38.27%
|
0.08
+237.50%
|
0.02
|
| Total Other Finance Cost |
|
—
|
-0.79
+35.86%
|
-1.24
-250.71%
|
-0.35
|
| Line Item | Trend | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Total Assets |
|
22.15
-48.56%
|
43.06
|
| Current Assets |
|
20.90
-49.93%
|
41.74
|
| Cash Cash Equivalents And Short Term Investments |
|
19.78
-50.41%
|
39.89
|
| Cash And Cash Equivalents |
|
9.29
-31.27%
|
13.52
|
| Other Short Term Investments |
|
10.49
-60.22%
|
26.37
|
| Receivables |
|
0.29
-37.04%
|
0.46
|
| Other Receivables |
|
0.29
-37.04%
|
0.46
|
| Prepaid Assets |
|
0.75
-42.77%
|
1.31
|
| Restricted Cash |
|
0.08
-1.30%
|
0.08
|
| Total Non Current Assets |
|
1.25
-5.50%
|
1.33
|
| Net PPE |
|
0.69
+18.44%
|
0.58
|
| Gross PPE |
|
0.91
+21.74%
|
0.74
|
| Accumulated Depreciation |
|
-0.22
-33.35%
|
-0.17
|
| Properties |
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
0.10
-1.94%
|
0.10
|
| Construction In Progress |
|
0.01
+0.00%
|
0.01
|
| Other Properties |
|
0.79
+26.52%
|
0.63
|
| Leases |
|
0.01
-12.50%
|
0.02
|
| Goodwill And Other Intangible Assets |
|
0.01
-42.71%
|
0.01
|
| Other Intangible Assets |
|
0.01
-42.71%
|
0.01
|
| Investments And Advances |
|
—
|
—
|
| Other Investments |
|
—
|
—
|
| Non Current Prepaid Assets |
|
0.56
-23.74%
|
0.73
|
| Other Non Current Assets |
|
—
|
—
|
| Total Liabilities Net Minority Interest |
|
5.15
-24.65%
|
6.84
|
| Current Liabilities |
|
4.84
-28.32%
|
6.75
|
| Payables And Accrued Expenses |
|
3.94
-22.25%
|
5.07
|
| Payables |
|
0.52
-69.43%
|
1.69
|
| Accounts Payable |
|
0.52
-69.43%
|
1.69
|
| Current Accrued Expenses |
|
3.42
+1.33%
|
3.38
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.82
-47.24%
|
1.56
|
| Current Debt And Capital Lease Obligation |
|
0.08
-38.21%
|
0.12
|
| Current Capital Lease Obligation |
|
0.08
-38.21%
|
0.12
|
| Total Non Current Liabilities Net Minority Interest |
|
0.32
+247.25%
|
0.09
|
| Long Term Debt And Capital Lease Obligation |
|
0.32
+247.25%
|
0.09
|
| Long Term Capital Lease Obligation |
|
0.32
+247.25%
|
0.09
|
| Stockholders Equity |
|
17.00
-53.08%
|
36.22
|
| Common Stock Equity |
|
17.00
-53.08%
|
36.22
|
| Capital Stock |
|
0.00
|
0.00
|
| Common Stock |
|
0.00
|
0.00
|
| Share Issued |
|
284.09
+22.12%
|
232.64
|
| Ordinary Shares Number |
|
284.09
+28.55%
|
221.00
|
| Treasury Shares Number |
|
11.64
+0.00%
|
11.64
|
| Additional Paid In Capital |
|
105.67
+4.36%
|
101.26
|
| Retained Earnings |
|
-88.68
-38.95%
|
-63.82
|
| Treasury Stock |
|
0.00
-100.00%
|
1.22
|
| Total Equity Gross Minority Interest |
|
17.00
-53.08%
|
36.22
|
| Total Capitalization |
|
17.00
-53.08%
|
36.22
|
| Working Capital |
|
16.06
-54.10%
|
34.99
|
| Invested Capital |
|
17.00
-53.08%
|
36.22
|
| Total Debt |
|
0.39
+83.18%
|
0.21
|
| Capital Lease Obligations |
|
0.39
+83.18%
|
0.21
|
| Net Tangible Assets |
|
16.99
-53.08%
|
36.21
|
| Tangible Book Value |
|
16.99
-53.08%
|
36.21
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-11.13
+27.66%
|
-15.39
+34.84%
|
-23.61
-15.91%
|
-20.37
|
| Cash Flow From Continuing Operating Activities |
|
-11.13
+27.66%
|
-15.39
+34.84%
|
-23.61
-15.91%
|
-20.37
|
| Net Income From Continuing Operations |
|
-8.99
+35.50%
|
-13.95
+42.43%
|
-24.22
+12.39%
|
-27.65
|
| Depreciation Amortization Depletion |
|
0.07
+32.08%
|
0.05
-20.90%
|
0.07
+15.52%
|
0.06
|
| Depreciation |
|
0.07
+32.08%
|
0.05
-20.90%
|
0.07
+15.52%
|
0.06
|
| Depreciation And Amortization |
|
0.07
+32.08%
|
0.05
-20.90%
|
0.07
+15.52%
|
0.06
|
| Other Non Cash Items |
|
0.01
|
—
|
—
|
—
|
| Stock Based Compensation |
|
0.62
+0.97%
|
0.62
-58.62%
|
1.49
-53.57%
|
3.21
|
| Change In Working Capital |
|
-2.83
-34.30%
|
-2.11
-122.68%
|
-0.95
-123.66%
|
4.01
|
| Change In Receivables |
|
-1.14
-134.70%
|
-0.49
-153.93%
|
0.90
+1510.94%
|
-0.06
|
| Change In Payables And Accrued Expense |
|
-1.38
+22.09%
|
-1.77
-57.05%
|
-1.13
-135.50%
|
3.17
|
| Change In Accrued Expense |
|
-1.20
+36.30%
|
-1.89
-4293.33%
|
0.04
-98.41%
|
2.82
|
| Change In Payable |
|
-0.18
-251.28%
|
0.12
+109.98%
|
-1.17
-432.95%
|
0.35
|
| Change In Account Payable |
|
-0.18
-251.28%
|
0.12
+109.98%
|
-1.17
-432.95%
|
0.35
|
| Change In Other Working Capital |
|
-0.31
-314.38%
|
0.15
+120.17%
|
-0.72
-180.80%
|
0.90
|
| Investing Cash Flow |
|
5.39
+134.65%
|
2.30
-85.53%
|
15.88
-18.71%
|
19.53
|
| Cash Flow From Continuing Investing Activities |
|
5.39
+134.65%
|
2.30
-85.53%
|
15.88
-18.71%
|
19.53
|
| Net PPE Purchase And Sale |
|
-0.00
|
0.00
+100.00%
|
-0.00
+95.59%
|
-0.07
|
| Purchase Of PPE |
|
-0.00
|
0.00
+100.00%
|
-0.00
+95.59%
|
-0.07
|
| Sale Of PPE |
|
—
|
0.00
|
0.00
|
0.00
|
| Capital Expenditure |
|
-0.00
|
—
|
-0.00
+95.59%
|
-0.07
|
| Net Investment Purchase And Sale |
|
—
|
—
|
—
|
19.60
|
| Purchase Of Investment |
|
—
|
—
|
—
|
—
|
| Sale Of Investment |
|
—
|
—
|
—
|
19.60
|
| Net Other Investing Changes |
|
5.39
+134.78%
|
2.30
-85.54%
|
15.88
-18.97%
|
19.60
|
| Financing Cash Flow |
|
7.16
-27.47%
|
9.87
+181.62%
|
3.50
+533.66%
|
-0.81
|
| Cash Flow From Continuing Financing Activities |
|
7.16
-27.47%
|
9.87
+181.62%
|
3.50
+533.66%
|
-0.81
|
| Net Common Stock Issuance |
|
7.14
-27.59%
|
9.87
+181.62%
|
3.50
+468.45%
|
-0.95
|
| Common Stock Payments |
|
—
|
0.00
|
0.00
+100.00%
|
-1.22
|
| Repurchase Of Capital Stock |
|
—
|
0.00
|
0.00
+100.00%
|
-1.22
|
| Proceeds From Stock Option Exercised |
|
0.01
|
0.00
|
0.00
-100.00%
|
0.14
|
| Net Other Financing Charges |
|
—
|
—
|
—
|
—
|
| Changes In Cash |
|
1.42
+143.99%
|
-3.22
+23.82%
|
-4.23
-157.02%
|
-1.65
|
| Beginning Cash Position |
|
6.15
-34.38%
|
9.37
-31.10%
|
13.60
-10.79%
|
15.24
|
| End Cash Position |
|
7.56
+23.05%
|
6.15
-34.38%
|
9.37
-31.10%
|
13.60
|
| Free Cash Flow |
|
-11.13
+27.64%
|
-15.39
+34.84%
|
-23.61
-15.54%
|
-20.44
|
| Income Tax Paid Supplemental Data |
|
—
|
—
|
—
|
0.01
|
| Common Stock Issuance |
|
7.14
-27.59%
|
9.87
+181.62%
|
3.50
+1212.36%
|
0.27
|
| Issuance Of Capital Stock |
|
7.14
-27.59%
|
9.87
+181.62%
|
3.50
+1212.36%
|
0.27
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42023-07-05 View
- 42023-06-20 View
- 42023-06-16 View
- 8-K2023-06-16 View
- 8-K2023-06-05 View
- 8-K2023-05-11 View
- 10-Q2023-05-11 View
- 42023-03-23 View
- 42023-03-23 View
- 42023-03-23 View
- 42023-03-23 View
- 10-K2023-03-20 View
- 8-K2023-02-21 View
- 8-K2023-02-21 View
- 8-K2023-01-11 View
- 42023-01-05 View
- 42023-01-05 View
- 8-K2023-01-03 View
- 42022-11-18 View
- 42022-11-17 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|